PPARA and metabolic dysfunction-associated steatohepatitis: These findings suggest that apigenin may support individuals with non-alcoholic steatohepatitis (NASH) by suppressing lipid metabolism and OS abnormalities via a new regulating mechanism of Nrf2 and PPAR (62).